MX349974B - Metodo para el tratamiento o profilaxis de trombosis o embolismo. - Google Patents

Metodo para el tratamiento o profilaxis de trombosis o embolismo.

Info

Publication number
MX349974B
MX349974B MX2013002191A MX2013002191A MX349974B MX 349974 B MX349974 B MX 349974B MX 2013002191 A MX2013002191 A MX 2013002191A MX 2013002191 A MX2013002191 A MX 2013002191A MX 349974 B MX349974 B MX 349974B
Authority
MX
Mexico
Prior art keywords
embolism
thrombosis
methods
clopidogrel
prophylaxis
Prior art date
Application number
MX2013002191A
Other languages
English (en)
Other versions
MX2013002191A (es
Inventor
Kumar Ashok
By Ju Nellithanath Thankachen
Original Assignee
Ipca Laboratories Ltd *
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45698045&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX349974(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ipca Laboratories Ltd * filed Critical Ipca Laboratories Ltd *
Publication of MX2013002191A publication Critical patent/MX2013002191A/es
Publication of MX349974B publication Critical patent/MX349974B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona un método para aminorar las desventajas de la droga en contra de las plaquetas llamada clopidogrel. El método de la presente invención comprende administrar un (S)-oxo-clopidogrel o su derivado de la Fórmula IIA en su forma de sal libre farmacéuticamente aceptable para aliviar los síntomas de trombosis o embolismo mediante el inhibir el agregado de plaquetas de sangre. También se proporciona una composición para el uso de tales métodos comprendiendo un (S)-oxo-clopidogrel o su derivado de la Formula IIA o una sal farmacéuticamente aceptable del mismo.
MX2013002191A 2010-08-26 2011-08-25 Metodo para el tratamiento o profilaxis de trombosis o embolismo. MX349974B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2388MU2010 2010-08-26
PCT/IN2011/000578 WO2012025942A1 (en) 2010-08-26 2011-08-25 Methods for the treatment or prophylaxis of thrombosis or embolism

Publications (2)

Publication Number Publication Date
MX2013002191A MX2013002191A (es) 2013-06-28
MX349974B true MX349974B (es) 2017-08-22

Family

ID=45698045

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013002191A MX349974B (es) 2010-08-26 2011-08-25 Metodo para el tratamiento o profilaxis de trombosis o embolismo.

Country Status (12)

Country Link
US (3) US8541422B2 (es)
EP (1) EP2613783B1 (es)
JP (1) JP2013536220A (es)
KR (1) KR20130101517A (es)
CN (1) CN103068383A (es)
AU (1) AU2011294757B2 (es)
BR (1) BR112013004165B1 (es)
CA (1) CA2808520C (es)
MX (1) MX349974B (es)
NZ (1) NZ606903A (es)
RU (1) RU2611662C2 (es)
WO (1) WO2012025942A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102120744B (zh) * 2010-02-02 2013-01-09 江苏威凯尔医药科技有限公司 光学活性2-羟基四氢噻吩并吡啶衍生物及其制备方法与在制药中的用途
EP2675813A4 (en) * 2011-06-27 2014-04-30 Ipca Lab Ltd ANTI THROMBOSIS CONNECTIONS
EP2668945A1 (de) * 2012-06-01 2013-12-04 Bayer Technology Services GmbH Genotyp- bzw. Phänotyp-basierte Arzeimittelformulierungen
CN103664990A (zh) * 2012-09-12 2014-03-26 江苏威凯尔医药科技有限公司 维卡格雷的制备方法
WO2014043895A1 (zh) * 2012-09-21 2014-03-27 北京普禄德医药科技有限公司 光学活性的2-羟基四氢噻吩并吡啶衍生物及其制备方法和用途
CN103720700A (zh) * 2012-10-10 2014-04-16 江苏威凯尔医药科技有限公司 含有阿斯匹林和维卡格雷的药用组合物
CN104418891B (zh) * 2013-08-28 2018-04-06 江苏威凯尔医药科技有限公司 水溶性2‑羟基四氢噻吩并吡啶衍生物的制备及其医药用途
CN103524528A (zh) * 2013-09-16 2014-01-22 吉林省博大伟业制药有限公司 一种改进的ⅱ型硫酸氢氯吡格雷结晶制备方法
CN104447867B (zh) * 2013-09-17 2017-12-26 江苏天士力帝益药业有限公司 一种噻吩并哌啶衍生物、制备方法及其应用
CN105153192B (zh) * 2014-09-02 2019-03-29 南京曼杰生物科技有限公司 取代的四氢噻吩并吡啶衍生物及其应用
CN107304215A (zh) * 2016-04-20 2017-10-31 陕西合成药业股份有限公司 噻吩吡啶类衍生物及其制备方法和用途
KR102532121B1 (ko) * 2017-10-18 2023-05-12 고려제약주식회사 돌미나리 추출물 및 항혈전제를 포함하는 항혈전용 조성물
CN115518066A (zh) * 2022-06-17 2022-12-27 成都施贝康生物医药科技有限公司 一种用于治疗抗凝血的药物组合物及应用
CN120518629A (zh) * 2025-07-24 2025-08-22 江苏威凯尔医药科技股份有限公司 一种维卡格雷的晶型及其制备方法和用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2530247B1 (fr) 1982-07-13 1986-05-16 Sanofi Sa Nouveaux derives de la thieno (3, 2-c) pyridine, leur procede de preparation et leur application therapeutique
FR2576901B1 (fr) * 1985-01-31 1987-03-20 Sanofi Sa Nouveaux derives de l'acide a-(oxo-2 hexahydro-2,4,5,6,7,7a thieno (3,2-c) pyridyl-5) phenyl acetique, leur procede de preparation et leur application therapeutique
FR2652579B1 (fr) * 1989-10-02 1992-01-24 Sanofi Sa Derives d'hydroxy-2 thiophene et furanne condenses avec un cycle azote, sur procede de preparation et leur application en therapeutique.
JPH10310586A (ja) * 1996-06-26 1998-11-24 Sankyo Co Ltd ヒドロピリジン類の新規医薬用途
WO1997049397A1 (en) 1996-06-26 1997-12-31 Sankyo Company, Limited Novel medicinal compositions of hydropyridines
CN101237868A (zh) * 2005-06-13 2008-08-06 伊兰制药国际有限公司 纳米粒氯吡格雷和阿司匹林组合制剂
RU2359681C1 (ru) * 2008-01-31 2009-06-27 Закрытое акционерное общество Научно-производственное предприятие "Тринита" Антитромботическая композиция на основе гепарина для перорального применения
CN101591344B (zh) 2008-05-27 2012-12-05 连云港恒邦医药科技有限公司 一种抗血栓的化合物、其制备方法和用途
CN101885730B (zh) 2009-05-13 2012-07-04 连云港恒邦医药科技有限公司 抗血栓的化合物
WO2011079407A1 (zh) 2009-12-28 2011-07-07 北京益君康医药技术有限公司 新的具有抗凝血作用的化合物
CN102120744B (zh) * 2010-02-02 2013-01-09 江苏威凯尔医药科技有限公司 光学活性2-羟基四氢噻吩并吡啶衍生物及其制备方法与在制药中的用途

Also Published As

Publication number Publication date
KR20130101517A (ko) 2013-09-13
AU2011294757A1 (en) 2013-02-28
CN103068383A (zh) 2013-04-24
AU2011294757B2 (en) 2015-11-05
CA2808520C (en) 2019-05-21
US20140018331A1 (en) 2014-01-16
WO2012025942A1 (en) 2012-03-01
EP2613783A4 (en) 2013-09-11
CA2808520A1 (en) 2012-03-01
BR112013004165B1 (pt) 2021-07-20
US8541422B2 (en) 2013-09-24
JP2013536220A (ja) 2013-09-19
MX2013002191A (es) 2013-06-28
US9321785B2 (en) 2016-04-26
EP2613783B1 (en) 2019-06-12
NZ606903A (en) 2015-05-29
RU2611662C2 (ru) 2017-02-28
BR112013004165A2 (pt) 2018-05-29
US20150307513A1 (en) 2015-10-29
RU2013113222A (ru) 2014-10-10
US20120053157A1 (en) 2012-03-01
EP2613783A1 (en) 2013-07-17

Similar Documents

Publication Publication Date Title
MX349974B (es) Metodo para el tratamiento o profilaxis de trombosis o embolismo.
PH12018501807A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of diseas
IL268960A (en) 7,6,5,4-Tetrahydroisoxazazole (4,5-c) Pyridin-3-ol (thip) for use in the treatment of broken x syndrome
AU2012214029A8 (en) Rorgammat inhibitors
MX2014002394A (es) Inhibidores de rock suaves, novedosos.
NZ744567A (en) Treatment of cancers using pi3 kinase isoform modulators
IN2014DN10670A (es)
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
MY180666A (en) Substituted pyrazolo [3,4-b] pyridines as medicaments
WO2014179564A8 (en) Thiazolopyrrolidine inhibitors of ror-gamma
UA109868C2 (ru) Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar)
MX2015016421A (es) Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
MX360634B (es) Inhibidores de 3-haloalilamina sustituidos de ssao y uso de los mismos.
NZ704266A (en) Inhibitors of alpha-crystallin aggregation for the treatment for cataract
MY183398A (en) Derivatives of azaindazole or diazaindazole type for treating pain
EA201690657A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ 3-(1H-ПИРАЗОЛ-4-ИЛ)-1H-ПИРРОЛО[2,3-c]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ NIK
MX2016006667A (es) Derivados de pirrolo-pirrolona y su uso como inhibidores.
MY183974A (en) Il17 and ifn-gamma inhibition for the treatment of autoimmune inflammation
MX2015016425A (es) Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades.
WO2013147649A3 (ru) ИНГИБИТОРЫ СИГНАЛЬНОГО ПУТИ PI3K/AKT/IKK/NF-kB, ИХ ФАРМАЦЕВТИЧЕСКИ ПРИЕМЛЕМЫЕ СОЛИ И СОДЕРЖАЩИЕ ИХ КОМПОЗИЦИИ ДЛЯ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ ВИРУСНЫХ ЗАБОЛЕВАНИЙ
CO6561789A2 (es) Método de tratamiento
MX2015012741A (es) Palbociclib deuterado.
IN2015DN01408A (es)
MX2015007940A (es) Compuestos tricíclicos como inhibidores de cftr.
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.

Legal Events

Date Code Title Description
FG Grant or registration